Company Filing History:
3 out of 8 
2 out of 3,539 
2 out of 1,324 
Years Active: 2009-2018
Title: Michael E Goldberg: Innovator in Ketamine Metabolite Research
Introduction
Michael E Goldberg is a prominent inventor based in Philadelphia, PA, known for his significant contributions to the field of pharmacology. He holds three patents that focus on the use of ketamine metabolites in treating various mental health conditions and chronic pain. His work has the potential to revolutionize treatment options for patients suffering from depression and neuropathic pain.
Latest Patents
Goldberg's latest patents include innovative pharmaceutical preparations that utilize (2R, 6R)-hydroxynorketamine and (S)-dehydronorketamine. These patents detail methods for treating bipolar depression, major depressive disorder, and chronic pain, including complex regional pain syndrome (CRPS). The disclosures emphasize the administration of purified ketamine metabolites or their prodrugs directly to patients, showcasing a novel approach to mental health treatment.
Career Highlights
Throughout his career, Michael E Goldberg has worked with esteemed organizations such as the Cooper Health System and the National Institutes of Health, a component of the US Department of Health & Human Services. His experience in these institutions has allowed him to collaborate on groundbreaking research and contribute to advancements in medical science.
Collaborations
Goldberg has collaborated with notable colleagues, including Irving William Wainer and Ruin Moaddel. These partnerships have further enriched his research and development efforts in the field of ketamine metabolite applications.
Conclusion
Michael E Goldberg's innovative work in the realm of ketamine metabolites positions him as a key figure in the ongoing quest for effective treatments for depression and chronic pain. His patents and collaborations reflect a commitment to improving patient outcomes through scientific advancement.